1. Pink Sheet
  2. >>Drug Safety

Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA

 
• By Cathy Kelly

A pilot project operated by the Reagan-Udall Foundation and funded by Pfizer will evaluate ways drug companies can use FDA’s Sentinel electronic data network to conduct independent post-market safety surveillance.

The Reagan-Udall Foundation and Pfizer Inc. are launching a pilot project to test approaches to conducting post-market drug safety research using FDA’s Sentinel data network without the agency’s involvement.

FDA is the only organization currently using the Sentinel post-market electronic data network, which has become a regular part of the agency’s safety surveillance activities for drugs, biologics and vaccines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.